Total
0
Shares
Source: AllCare Physio/ Facebook
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Healthia (HLA) purchases two AllCare Physiotherapy stores and a John Holme Optometrist for $2.46 million
  • The company has also entered into an agreement to purchase Anytime Physio in Newstead, Queensland
  • The newly purchased business are expected to contribute a revenue of $3.95 million and EBITDA of $640,000
  • Managing Director, Wesley Coote, says the company’s vision is to build the leading allied health care business in the Australian market
  • On market close, Healthia was down 6.25 per cent, trading at $1.80 per share

Healthia (HLA) has agreed to purchase two AllCare Physiotherapy stores and a John Holme Optometrist for $2.46 million.

The physiotherapy clinics are located in Hobart, Tasmania, while the optometrist includes two stores in Northern Queensland.

The company has also entered into an agreement to purchase Anytime Physio in Newstead, Queensland.

The newly purchased businesses are expected to contribute a revenue of $3.95 million and earnings before interest, tax, depreciation and amortisation (EBITDA) of $640,000.

Managing Director, Wesley Coote, said the company’s vision is to build the leading allied health care business in the Australian market.

“Our key target sectors of Bodies and Minds, Feet and Ankles, and Eyes and Ears have a collective addressable market of $9.8 billion,” Mr Coote said.

“We have a proven management team and a clinician and patient first culture and are excited to have these businesses joining our growing allied health network.”

Since listing on the ASX in September 2018, Healthia has grown its portfolio of allied health businesses from 104 to 217. This marks a 109 per cent growth and the company will continue adding value to its portfolio of assets.

On market close, Healthia was down 6.25 per cent, trading at $1.80 per share.

HLA by the numbers
More From The Market Herald
Anteris Technologies (ASX:AVR) - CEO, Wayne Paterson

" Anteris Technologies (ASX:AVR) eyes $5m for DurAVR

Anteris Technologies (AVR) has placed 625,000 new ordinary shares to Melbourne-based global investor L1 Capital to raise $5 million.
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo (ASX:AT1) approved to supply and advertise HIV Self-Test

Atomo Diagnostics (AT1) can now supply its HIV self-test to a greater variety of organisations and begin advertising thanks to recent changes made
Starpharma (ASX:SPL) - CEO, Dr Jackie Fairley

" Starpharma (ASX:SPL) signs VIRALEZE supply deal for Vietnam

Starpharma (SPL) has penned an initial deal to distribute and supply its VIRALEZE antiviral nasal spray in Vietnam.
Paradigm Biopharmaceuticals (ASX:PAR) - Chief Medical Officer and Executive Director, Dr Donna Skerrett

" Paradigm Biopharmaceuticals (ASX:PAR) amends clinical trial

Paradigm Biopharmaceuticals (PAR) has made amendments to its clinical trial protocol for knee osteoarthritis treatment.